EU panel supports approval of 4 new drugs

04/29/2013 | Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Roche Holding and Curis' advanced basal cell carcinoma drug Erivedge as well as Astellas Pharma and Medivation's prostate cancer treatment Xtandi. Genzyme's MAC1, a tissue-engineered treatment for cartilage defects, and Vivus' erectile dysfunction drug Spedra also received approval recommendations from the panel.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC